FDA NDA · NDA208775

ABACAVIR AND LAMIVUDINE

Sponsor: CIPLA LIMITED

APPLICATION

NDA208775

TYPE

NDA

ROUTE

ORAL

DOSAGE FORM

TABLET, FOR SUSPENSION

MARKETING STATUS

None (Tentative Approval)

Products

ABACAVIR AND LAMIVUDINENone (Tentative Approval)

ABACAVIR 120MG, LAMIVUDINE 60MG · TABLET, FOR SUSPENSION · ORAL

2017-04-06Type 3 - New Dosage Form · Original · standardTA

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.